Daniel B.  Soland net worth and biography

Daniel Soland Biography and Net Worth

Daniel Soland joined Idera as Senior Vice President and Chief Operating Officer in January 2021. Mr. Soland previously served as the Chief Executive Officer of uniQure N.V. and, prior to that, Senior Vice President & COO of ViroPharma Inc. While at ViroPharma, Mr. Soland managed the commercial, manufacturing, and quality organizations, helped build the company’s commercial infrastructure in the U.S., Europe, and Canada, and led the launch of Cinryze® (C1 esterase inhibitor [human]), one of the most successful ultra-orphan drug launches in the U.S. Mr. Soland also served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the Board of Directors of Acadia Pharmaceuticals, Inc., DBV Technologies SA, and KalVista Pharmaceuticals, Inc. Mr. Soland earned his B.S. in Pharmacy from the University of Iowa.

What is Daniel B. Soland's net worth?

The estimated net worth of Daniel B. Soland is at least $0.00 as of August 1st, 2023. Mr. Soland owns 20,000 shares of Idera Pharmaceuticals stock worth more than $0 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Soland may own. Learn More about Daniel B. Soland's net worth.

How do I contact Daniel B. Soland?

The corporate mailing address for Mr. Soland and other Idera Pharmaceuticals executives is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. Idera Pharmaceuticals can also be reached via phone at (484) 348-1600 and via email at [email protected]. Learn More on Daniel B. Soland's contact information.

Has Daniel B. Soland been buying or selling shares of Idera Pharmaceuticals?

Daniel B. Soland has not been actively trading shares of Idera Pharmaceuticals during the last quarter. Most recently, on Friday, June 18th, Daniel B. Soland bought 50,000 shares of Idera Pharmaceuticals stock. The stock was acquired at an average cost of $1.19 per share, with a total value of $59,500.00. Following the completion of the transaction, the chief operating officer now directly owns 78,843 shares of the company's stock, valued at $93,823.17. Learn More on Daniel B. Soland's trading history.

Who are Idera Pharmaceuticals' active insiders?

Idera Pharmaceuticals' insider roster includes John Kirby (CFO), Bryant Lim (SVP), Daniel Soland (COO), and Elizabeth Tarka (Insider). Learn More on Idera Pharmaceuticals' active insiders.

Daniel B. Soland Insider Trading History at Idera Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/18/2021Buy50,000$1.19$59,500.0078,843View SEC Filing Icon  
3/5/2021Buy10,000$3.90$39,000.00
See Full Table

Daniel B. Soland Buying and Selling Activity at Idera Pharmaceuticals

This chart shows Daniel B Soland's buying and selling at Idera Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Idera Pharmaceuticals Company Overview

Idera Pharmaceuticals logo
Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.50
Low: $0.17
High: $7.23

2 Week Range

Now: N/A

Volume

21,870 shs

Average Volume

464,030 shs

Market Capitalization

$450.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25